Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
In the latest session, Ionis Pharmaceuticals Inc (NASDAQ: IONS) closed at $68.4 up 3.95% from its previous closing price of $65.8. In other words, the price has increased by $3.95 from its previous closing price. On the day, 3.0 million shares were traded. IONS stock price reached its highest trading level at $68.41 during the session, while it also had its lowest trading level at $65.97.
Ratios:
For a deeper understanding of Ionis Pharmaceuticals Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.86 and its Current Ratio is at 2.87. In the meantime, Its Debt-to-Equity ratio is 3.13 whereas as Long-Term Debt/Eq ratio is at 2.11.
On September 03, 2025, BMO Capital Markets Upgraded its rating to Outperform which previously was Market Perform but kept the price unchanged to $70.
Morgan Stanley Upgraded its Equal-Weight to Overweight on July 31, 2025, while the target price for the stock was maintained at $62.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Oct 01 ’25 when WENDER JOSEPH H sold 16,800 shares for $65.50 per share. The transaction valued at 1,100,385 led to the insider holds 92,035 shares of the business.
Swayze Eric sold 14,142 shares of IONS for $934,662 on Oct 01 ’25. The EVP Research now owns 37,302 shares after completing the transaction at $66.09 per share. On Oct 02 ’25, another insider, Swayze Eric, who serves as the EVP Research of the company, sold 12,972 shares for $66.23 each. As a result, the insider received 859,082 and left with 37,302 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IONS now has a Market Capitalization of 10902360064 and an Enterprise Value of 10593392640. For the stock, the TTM Price-to-Sale (P/S) ratio is 11.54 while its Price-to-Book (P/B) ratio in mrq is 17.24. Its current Enterprise Value per Revenue stands at 11.221 whereas that against EBITDA is -41.515.
Stock Price History:
The Beta on a monthly basis for IONS is 0.32, which has changed by 0.80427325 over the last 52 weeks, in comparison to a change of 0.16766965 over the same period for the S&P500. Over the past 52 weeks, IONS has reached a high of $66.25, while it has fallen to a 52-week low of $23.95. The 50-Day Moving Average of the stock is 32.30%, while the 200-Day Moving Average is calculated to be 77.96%.
Shares Statistics:
For the past three months, IONS has traded an average of 2.43M shares per day and 2229960 over the past ten days. A total of 159.20M shares are outstanding, with a floating share count of 158.16M. Insiders hold about 0.77% of the company’s shares, while institutions hold 106.68% stake in the company. Shares short for IONS as of 1757894400 were 11972594 with a Short Ratio of 4.93, compared to 1755216000 on 10785168. Therefore, it implies a Short% of Shares Outstanding of 11972594 and a Short% of Float of 9.9700004.
Earnings Estimates
. The current rating of Ionis Pharmaceuticals Inc (IONS) reflects the combined expertise of 8.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is -$1.11, with high estimates of -$0.95 and low estimates of -$1.37.
Analysts are recommending an EPS of between -$1.63 and -$2.49 for the fiscal current year, implying an average EPS of -$1.92. EPS for the following year is -$1.89, with 11.0 analysts recommending between -$0.46 and -$3.17.
Revenue Estimates
A total of 19 analysts believe the company’s revenue will be $131.75M this quarter.It ranges from a high estimate of $172.61M to a low estimate of $111.1M. As of. The current estimate, Ionis Pharmaceuticals Inc’s year-ago sales were $134MFor the next quarter, 19 analysts are estimating revenue of $145.21M. There is a high estimate of $218M for the next quarter, whereas the lowest estimate is $120.54M.
A total of 24 analysts have provided revenue estimates for IONS’s current fiscal year. The highest revenue estimate was $961.6M, while the lowest revenue estimate was $832.78M, resulting in an average revenue estimate of $866.36M. In the same quarter a year ago, actual revenue was $705MBased on 23 analysts’ estimates, the company’s revenue will be $900.64M in the next fiscal year. The high estimate is $1.15B and the low estimate is $687.38M.
